Please login to the form below

ViraTherapeutics

This page shows the latest ViraTherapeutics news and features for those working in and with pharma, biotech and healthcare.

by ViraTherapeutics in 2016.

Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

Boehringer buys into oncolytic viruses via 210m ViraTherapeutics deal. Option to acquire the Austrian biotech after phase I trials remains open to Boehringer . ... Boehringer Ingelheim has boosted its position in immuno-oncology by licensing an

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Deal Watch September 2016

With a headline value of $235m Boehringer Ingelheim entered into a collaboration with ViraTherapeutics to develop an oncolytic virus therapy platform. ... Boehringer also secured the option to acquire ViraTherapeutics after development of VSV-GP.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Add my company

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...